Key facts
- It has raised $217.6M; the latest was Later Stage VC ($71.9M) in Feb 2026.
- Notable investors include Puhua Capital, Lapam Capital, CAS Investment Management, Shanghai Pudong Venture Capital, Shanghai Lingang Economic Development — 24 tracked in total.
- Status: Privately Held (backing).
Investors
24+- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Cascade Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Cascade Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cascade Pharma
Developer of nuclear receptor drugs intended to provide new therapies for chronic liver diseases. The company develops innovative drugs targeting nuclear receptors, enabling healthcare professionals to better treat patients with metabolic liver diseases and inflammation.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2017
- Employees
- 29
- Website
- cascadepharm.com/
- Ownership
- Privately Held (backing)
Cascade Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cascade Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cascade Pharma in its N-PORT filings yet. We sweep new filings monthly.